While anti-PD-1 therapies, such as nivolumab and pembrolizumab, have demonstrated significant efficacy in cancer treatment, not all patients respond to these therapies, and some experience severe immune-related adverse events (irAEs). This evidence concerns the gene PDCD1 and cancer.